CAPR vs UNH

Capricor Therapeutics (CAPR) maintains its high-risk, high-reward profile, with its valuation hinging primarily on the upcoming FDA PDUFA date of August 22, 2026, for Deramiocel in Duchenne Muscular Dystrophy (DMD). The multi-billion dollar TAM and Deramiocel’s unique cell therapy mechanism offer substantial 10x growth potential if approved. Despite a strong cash position of $278.6 million providi...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...